Back to Search Start Over

Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer.

Authors :
Chae, Sun Young
Son, Hye Joo
Lee, Dong Yun
Shin, Eonwoo
Oh, Jungsu S.
Seo, Seung Yeon
Baek, Sora
Kim, Ji Young
Na, Sae Jung
Moon, Dae Hyuk
Source :
EJNMMI Research; 5/24/2020, Vol. 10 Issue 1, p1-9, 9p
Publication Year :
2020

Abstract

Background: To compare the diagnostic sensitivity of [<superscript>18</superscript>F]fluoroestradiol ([<superscript>18</superscript>F]FES) and [<superscript>18</superscript>F]fluorodeoxyglucose ([<superscript>18</superscript>F]FDG) positron emission tomography/computed tomography (PET/CT) for breast cancer recurrence in patients with estrogen receptor (ER)-positive primary breast cancer. Methods: Our database of consecutive patients enrolled in a previous prospective cohort study to assess [<superscript>18</superscript>F]FES PET/CT was reviewed to identify eligible patients who had ER-positive primary breast cancer with suspected first recurrence at presentation and who underwent [<superscript>18</superscript>F]FDG PET/CT. The sensitivity of qualitative [<superscript>18</superscript>F]FES and [<superscript>18</superscript>F]FDG PET/CT interpretations was assessed, comparing them with histological diagnoses. Results: Of the 46 enrolled patients, 45 were confirmed as having recurrent breast cancer, while one was diagnosed with chronic granulomatous inflammation. Forty (89%) patients were ER-positive, four (9%) were ER-negative, and one (2%) patient did not undergo an ER assay. The sensitivity of [<superscript>18</superscript>F]FES PET/CT was 71.1% (32/45, 95% CI, 55.7–83.6), while that of [<superscript>18</superscript>F]FDG PET/CT was 80.0% (36/45, 95% CI, 65.4–90.4) with a threshold of positive interpretation, and 93.3% (42/45, 95% CI, 81.7–98.6) when a threshold of equivocal was used. There was no significant difference in sensitivity between [<superscript>18</superscript>F]FES and [<superscript>18</superscript>F]FDG PET/CT (P = 0.48) with a threshold of positive [<superscript>18</superscript>F]FDG uptake, but the sensitivity of [<superscript>18</superscript>F]FDG was significantly higher than [<superscript>18</superscript>F]FES (P = 0.013) with a threshold of equivocal [<superscript>18</superscript>F]FDG uptake. One patient with a benign lesion showed negative [<superscript>18</superscript>F]FES but positive [<superscript>18</superscript>F]FDG uptake. Conclusions: The restaging of patients who had ER-positive primary breast cancer and present with recurrent disease may include [<superscript>18</superscript>F]FES PET/CT as an initial test when standard imaging studies are equivocal or suspicious. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2191219X
Volume :
10
Issue :
1
Database :
Complementary Index
Journal :
EJNMMI Research
Publication Type :
Academic Journal
Accession number :
143396731
Full Text :
https://doi.org/10.1186/s13550-020-00643-z